FI20176142A1 - Förfaranden för att fastställa den terapeutiska verkan hos snabbverkande antidepressanter och individualiserad antidepressantterapi i anslutning därtill - Google Patents

Förfaranden för att fastställa den terapeutiska verkan hos snabbverkande antidepressanter och individualiserad antidepressantterapi i anslutning därtill Download PDF

Info

Publication number: FI20176142A1
Authority: FI; Finland
Prior art keywords: rapid; acting; antidepressant; therapeutic efficacy; acting antidepressant
Prior art date: 2017-12-21

Application number

FI20176142A

Other languages

English (en)

Finnish (fi)

Other versions

FI128750B (sv

Inventor

Tomi Rantamäki

Samuel Kohtala

Wiebke Theilmann

Original Assignee

Helsingin Yliopisto

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-12-21

Filing date

2017-12-21

Publication date

2019-06-22

2017-12-21 Application filed by Helsingin Yliopisto filed Critical Helsingin Yliopisto

2017-12-21 Priority to FI20176142A priority Critical patent/FI128750B/sv

2018-12-20 Priority to PCT/FI2018/050954 priority patent/WO2019122525A1/en

2019-06-22 Publication of FI20176142A1 publication Critical patent/FI20176142A1/sv

2020-11-30 Application granted granted Critical

2020-11-30 Publication of FI128750B publication Critical patent/FI128750B/sv

Links

239000000935 antidepressant agent Substances 0.000 title claims abstract description 263
229940005513 antidepressants Drugs 0.000 title claims abstract description 263
230000001430 anti-depressive effect Effects 0.000 title claims abstract description 231
238000000034 method Methods 0.000 title claims abstract description 92
230000001225 therapeutic effect Effects 0.000 title claims abstract description 79
238000002560 therapeutic procedure Methods 0.000 title abstract description 14
238000011282 treatment Methods 0.000 claims abstract description 113
238000012544 monitoring process Methods 0.000 claims abstract description 74
238000012216 screening Methods 0.000 claims abstract description 10
230000010355 oscillation Effects 0.000 claims description 177
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 122
230000001537 neural effect Effects 0.000 claims description 113
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 61
210000004556 brain Anatomy 0.000 claims description 61
229960003299 ketamine Drugs 0.000 claims description 61
239000001272 nitrous oxide Substances 0.000 claims description 59
101150056950 Ntrk2 gene Proteins 0.000 claims description 55
230000005764 inhibitory process Effects 0.000 claims description 31
230000011664 signaling Effects 0.000 claims description 28
230000000144 pharmacologic effect Effects 0.000 claims description 23
230000001054 cortical effect Effects 0.000 claims description 19
230000005284 excitation Effects 0.000 claims description 18
238000002635 electroconvulsive therapy Methods 0.000 claims description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
206010010904 Convulsion Diseases 0.000 claims description 11
108090000623 proteins and genes Proteins 0.000 claims description 11
208000019901 Anxiety disease Diseases 0.000 claims description 9
KGPPDNUWZNWPSI-UHFFFAOYSA-N flurotyl Chemical group FC(F)(F)COCC(F)(F)F KGPPDNUWZNWPSI-UHFFFAOYSA-N 0.000 claims description 9
229950000929 flurotyl Drugs 0.000 claims description 9
208000012902 Nervous system disease Diseases 0.000 claims description 8
230000000638 stimulation Effects 0.000 claims description 8
230000003281 allosteric effect Effects 0.000 claims description 7
230000001010 compromised effect Effects 0.000 claims description 7
230000001624 sedative effect Effects 0.000 claims description 7
SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 claims description 6
206010012335 Dependence Diseases 0.000 claims description 6
230000036506 anxiety Effects 0.000 claims description 6
238000002582 magnetoencephalography Methods 0.000 claims description 6
239000000932 sedative agent Substances 0.000 claims description 6
230000003542 behavioural effect Effects 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 5
208000004296 neuralgia Diseases 0.000 claims description 5
208000021722 neuropathic pain Diseases 0.000 claims description 5
208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
238000011491 transcranial magnetic stimulation Methods 0.000 claims description 4
CFBVGSWSOJBYGC-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexan-1-one Chemical compound C=1C=CC=C(Cl)C=1C1(N)CCCC(O)C1=O CFBVGSWSOJBYGC-UHFFFAOYSA-N 0.000 claims description 3
QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 claims description 3
208000010340 Sleep Deprivation Diseases 0.000 claims description 3
230000008484 agonism Effects 0.000 claims description 3
230000001022 anti-muscarinic effect Effects 0.000 claims description 3
HSWPZIDYAHLZDD-UHFFFAOYSA-N atipamezole Chemical compound C1C2=CC=CC=C2CC1(CC)C1=CN=CN1 HSWPZIDYAHLZDD-UHFFFAOYSA-N 0.000 claims description 3
239000003150 biochemical marker Substances 0.000 claims description 3
230000017531 blood circulation Effects 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 3
QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 claims description 3
230000003252 repetitive effect Effects 0.000 claims description 3
230000000241 respiratory effect Effects 0.000 claims description 3
231100000430 skin reaction Toxicity 0.000 claims description 3
206010020843 Hyperthermia Diseases 0.000 claims description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
230000008485 antagonism Effects 0.000 claims description 2
230000000747 cardiac effect Effects 0.000 claims description 2
238000001816 cooling Methods 0.000 claims description 2
229930195712 glutamate Natural products 0.000 claims description 2
230000036031 hyperthermia Effects 0.000 claims description 2
230000001939 inductive effect Effects 0.000 claims description 2
230000007384 vagal nerve stimulation Effects 0.000 claims description 2
230000002631 hypothermal effect Effects 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 27
238000009509 drug development Methods 0.000 abstract description 2
238000007877 drug screening Methods 0.000 abstract description 2
239000003623 enhancer Substances 0.000 abstract description 2
230000000694 effects Effects 0.000 description 46
230000026731 phosphorylation Effects 0.000 description 33
238000006366 phosphorylation reaction Methods 0.000 description 33
230000004044 response Effects 0.000 description 24
241001465754 Metazoa Species 0.000 description 23
108020004414 DNA Proteins 0.000 description 22
108091034117 Oligonucleotide Proteins 0.000 description 22
206010001497 Agitation Diseases 0.000 description 20
230000001154 acute effect Effects 0.000 description 20
229940079593 drug Drugs 0.000 description 16
HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 14
229960002140 medetomidine Drugs 0.000 description 14
210000002569 neuron Anatomy 0.000 description 14
238000012360 testing method Methods 0.000 description 14
241000699670 Mus sp. Species 0.000 description 12
206010039897 Sedation Diseases 0.000 description 12
230000004913 activation Effects 0.000 description 12
230000004075 alteration Effects 0.000 description 12
239000007789 gas Substances 0.000 description 11
230000036280 sedation Effects 0.000 description 11
208000024891 symptom Diseases 0.000 description 11
241000699666 Mus <mouse, genus> Species 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
239000005557 antagonist Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000007924 injection Substances 0.000 description 10
210000002442 prefrontal cortex Anatomy 0.000 description 10
-1 Arc Proteins 0.000 description 9
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 9
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 9
108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 9
102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 9
230000033228 biological regulation Effects 0.000 description 9
229940077737 brain-derived neurotrophic factor Drugs 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
101150035467 BDNF gene Proteins 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
230000001052 transient effect Effects 0.000 description 8
230000009471 action Effects 0.000 description 7
201000010099 disease Diseases 0.000 description 7
239000005554 hypnotics and sedatives Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 7
208000020401 Depressive disease Diseases 0.000 description 6
108700002232 Immediate-Early Genes Proteins 0.000 description 6
102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 6
108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 6
230000000763 evoking effect Effects 0.000 description 6
230000014509 gene expression Effects 0.000 description 6
230000003284 homeostatic effect Effects 0.000 description 6
230000009286 beneficial effect Effects 0.000 description 5
230000003993 interaction Effects 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
230000035939 shock Effects 0.000 description 5
206010054089 Depressive symptom Diseases 0.000 description 4
ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 description 4
102000043136 MAP kinase family Human genes 0.000 description 4
108091054455 MAP kinase family Proteins 0.000 description 4
241000283984 Rodentia Species 0.000 description 4
230000003444 anaesthetic effect Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000000090 biomarker Substances 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
229950004346 gaboxadol Drugs 0.000 description 4
230000000848 glutamatergic effect Effects 0.000 description 4
VKJGQKRRULDFCI-UHFFFAOYSA-N hocpca Chemical compound OC1CCC(C(O)=O)=C1 VKJGQKRRULDFCI-UHFFFAOYSA-N 0.000 description 4
208000014674 injury Diseases 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
208000015122 neurodegenerative disease Diseases 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
230000008733 trauma Effects 0.000 description 4
206010002091 Anaesthesia Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
108010025020 Nerve Growth Factor Proteins 0.000 description 3
102000007072 Nerve Growth Factors Human genes 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
229920005372 Plexiglas® Polymers 0.000 description 3
208000028017 Psychotic disease Diseases 0.000 description 3
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
206010041349 Somnolence Diseases 0.000 description 3
102000001435 Synapsin Human genes 0.000 description 3
108050009621 Synapsin Proteins 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000000994 depressogenic effect Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000002045 lasting effect Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
210000000653 nervous system Anatomy 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
230000003534 oscillatory effect Effects 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
238000001671 psychotherapy Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
102000015534 trkB Receptor Human genes 0.000 description 3
108010064880 trkB Receptor Proteins 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
238000001262 western blot Methods 0.000 description 3
CSHJCESYHRWFCE-UHFFFAOYSA-N 2-amino-3-hydroxy-2-(5-methyl-1,2-oxazol-4-yl)propanoic acid Chemical compound CC=1ON=CC=1C(N)(CO)C(O)=O CSHJCESYHRWFCE-UHFFFAOYSA-N 0.000 description 2
ZDZDSZQYRBZPNN-UHFFFAOYSA-N 4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate;hydrochloride Chemical compound Cl.C1NCCC2=C1ONC2=O ZDZDSZQYRBZPNN-UHFFFAOYSA-N 0.000 description 2
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
102000003678 AMPA Receptors Human genes 0.000 description 2
108090000078 AMPA Receptors Proteins 0.000 description 2
102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
108010085238 Actins Proteins 0.000 description 2
102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 2
208000020925 Bipolar disease Diseases 0.000 description 2
206010010144 Completed suicide Diseases 0.000 description 2
101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 2
101150059401 EGR2 gene Proteins 0.000 description 2
102000001267 GSK3 Human genes 0.000 description 2
101150112014 Gapdh gene Proteins 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
102000010029 Homer Scaffolding Proteins Human genes 0.000 description 2
108010077223 Homer Scaffolding Proteins Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 2
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
206010027951 Mood swings Diseases 0.000 description 2
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
102000004230 Neurotrophin 3 Human genes 0.000 description 2
108090000742 Neurotrophin 3 Proteins 0.000 description 2
102000003683 Neurotrophin-4 Human genes 0.000 description 2
108090000099 Neurotrophin-4 Proteins 0.000 description 2
238000011529 RT qPCR Methods 0.000 description 2
208000032140 Sleepiness Diseases 0.000 description 2
208000021017 Weight Gain Diseases 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000001668 ameliorated effect Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229960003002 atipamezole Drugs 0.000 description 2
208000028683 bipolar I disease Diseases 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
238000007405 data analysis Methods 0.000 description 2
230000006735 deficit Effects 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
230000009429 distress Effects 0.000 description 2
238000001378 electrochemiluminescence detection Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000002964 excitative effect Effects 0.000 description 2
238000010304 firing Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
229960004801 imipramine Drugs 0.000 description 2
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
208000024714 major depressive disease Diseases 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
230000008062 neuronal firing Effects 0.000 description 2
230000007996 neuronal plasticity Effects 0.000 description 2
229940032018 neurotrophin 3 Drugs 0.000 description 2
229940097998 neurotrophin 4 Drugs 0.000 description 2
235000013842 nitrous oxide Nutrition 0.000 description 2
238000011458 pharmacological treatment Methods 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
239000013641 positive control Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
229960002646 scopolamine Drugs 0.000 description 2
208000012672 seasonal affective disease Diseases 0.000 description 2
230000007958 sleep Effects 0.000 description 2
208000019116 sleep disease Diseases 0.000 description 2
230000037321 sleepiness Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
230000003956 synaptic plasticity Effects 0.000 description 2
230000009897 systematic effect Effects 0.000 description 2
230000001755 vocal effect Effects 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
CFBVGSWSOJBYGC-ZYHUDNBSSA-N (2r,6r)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexan-1-one Chemical compound C=1C=CC=C(Cl)C=1[C@]1(N)CCC[C@@H](O)C1=O CFBVGSWSOJBYGC-ZYHUDNBSSA-N 0.000 description 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
101150029062 15 gene Proteins 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
FHCSBLWRGCOVPT-UHFFFAOYSA-N AZD2858 Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C(=O)NC=2C=NC=CC=2)C=C1 FHCSBLWRGCOVPT-UHFFFAOYSA-N 0.000 description 1
102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 1
101710177131 Activity-regulated cytoskeleton-associated protein Proteins 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000007415 Anhedonia Diseases 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
241001137251 Corvidae Species 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
101150117962 DUSP1 gene Proteins 0.000 description 1
206010012374 Depressed mood Diseases 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
101150114117 EGR1 gene Proteins 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010016374 Feelings of worthlessness Diseases 0.000 description 1
108010001483 Glycogen Synthase Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010021033 Hypomenorrhoea Diseases 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
101100444898 Mus musculus Egr1 gene Proteins 0.000 description 1
101100517384 Mus musculus Ntrk2 gene Proteins 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
201000009916 Postpartum depression Diseases 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
241000149788 Pseudophryne major Species 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108091005682 Receptor kinases Proteins 0.000 description 1
101100412088 Schizosaccharomyces pombe (strain 972 / ATCC 24843) rec10 gene Proteins 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000005937 Tropomyosin Human genes 0.000 description 1
108010030743 Tropomyosin Proteins 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229940125516 allosteric modulator Drugs 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003561 anti-manic effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000025748 atypical depressive disease Diseases 0.000 description 1
230000035578 autophosphorylation Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
208000025307 bipolar depression Diseases 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000007177 brain activity Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000002060 circadian Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
208000024732 dysthymic disease Diseases 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
108091008592 enzyme-linked receptors Proteins 0.000 description 1
102000027412 enzyme-linked receptors Human genes 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
230000009206 glutamatergic signaling Effects 0.000 description 1
210000004884 grey matter Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000026781 habituation Effects 0.000 description 1
102000006261 human tropomyosin-related kinase-B Human genes 0.000 description 1
108010058135 human tropomyosin-related kinase-B Proteins 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000008279 neurobiological mechanism Effects 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
238000002610 neuroimaging Methods 0.000 description 1
230000004007 neuromodulation Effects 0.000 description 1
230000008587 neuronal excitability Effects 0.000 description 1
230000004112 neuroprotection Effects 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
238000011338 personalized therapy Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000865 phosphorylative effect Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
235000015108 pies Nutrition 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940126027 positive allosteric modulator Drugs 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
239000000092 prognostic biomarker Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
239000003909 protein kinase inhibitor Substances 0.000 description 1
239000000007 protein synthesis inhibitor Substances 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000002385 psychotomimetic effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
239000003087 receptor blocking agent Substances 0.000 description 1
229940075993 receptor modulator Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000007261 regionalization Effects 0.000 description 1
231100000812 repeated exposure Toxicity 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
210000004761 scalp Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000003238 somatosensory effect Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
108010061506 tau-protein kinase Proteins 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/369—Electroencephalography [EEG]
- A61B5/372—Analysis of electroencephalograms
- A61B5/374—Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
- A61B5/165—Evaluating the state of mind, e.g. depression, anxiety

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pathology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Heart & Thoracic Surgery (AREA)
Biophysics (AREA)
Medical Informatics (AREA)
Surgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Psychology (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

FI20176142A 2017-12-21 2017-12-21 Förfaranden för att fastställa den terapeutiska verkan hos snabbverkande antidepressanter och individualiserad antidepressantterapi i anslutning därtill FI128750B (sv)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
FI20176142A FI128750B (sv)	2017-12-21	2017-12-21	Förfaranden för att fastställa den terapeutiska verkan hos snabbverkande antidepressanter och individualiserad antidepressantterapi i anslutning därtill
PCT/FI2018/050954 WO2019122525A1 (en)	2017-12-21	2018-12-20	Methods for determining the effect of rapid-acting antidepressants and personalized antidepressant therapy related thereto

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FI20176142A FI128750B (sv)	2017-12-21	2017-12-21	Förfaranden för att fastställa den terapeutiska verkan hos snabbverkande antidepressanter och individualiserad antidepressantterapi i anslutning därtill

Publications (2)

Publication Number	Publication Date
FI20176142A1 true FI20176142A1 (sv)	2019-06-22
FI128750B FI128750B (sv)	2020-11-30

Family

ID=65228580

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI20176142A FI128750B (sv)	2017-12-21	2017-12-21	Förfaranden för att fastställa den terapeutiska verkan hos snabbverkande antidepressanter och individualiserad antidepressantterapi i anslutning därtill

Country Status (2)

Country	Link
FI (1)	FI128750B (sv)
WO (1)	WO2019122525A1 (sv)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10947257B2 (en)	2017-10-09	2021-03-16	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11564935B2 (en)	2019-04-17	2023-01-31	Compass Pathfinder Limited	Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US12459965B2 (en)	2017-10-09	2025-11-04	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH12022553135A1 (en)	2020-05-19	2024-03-04	Cybin Irl Ltd	Deuterated tryptamine derivatives and methods of use
CN112545515B (zh) *	2020-12-04	2022-07-08	清华大学	竞争压力下射击表现检测及评估方法及装置
EP4486448A1 (en)	2022-03-04	2025-01-08	Reset Pharmaceuticals, Inc.	Co-crystals or salts comprising psilocin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8521270B2 (en) *	2006-06-05	2013-08-27	The Regents Of The University Of California	Quantitative EEG method to identify individuals at risk for adverse antidepressant effects
US20080159958A1 (en) *	2006-12-27	2008-07-03	Abbott Laboratories	Determination of histamine-3 bioactivity
EP2437658B1 (en)	2009-06-03	2019-08-21	MYnd Analytics, Inc.	Method for assessing the susceptibility of a human individual suffering from a psychiatric or neurological disorder to neuromodulation treatment
EP3125902B1 (en) *	2014-03-31	2020-09-16	University of Maryland, Baltimore	Use of negative modulators of gaba receptors containing alpha5 subunits as fast acting antidepressants
WO2015175531A1 (en)	2014-05-12	2015-11-19	Steerwasher, Llc	Compositions and methods for treating depressive disorders
WO2016029211A1 (en)	2014-08-22	2016-02-25	The General Hospital Corporation	Systems and methods for discovery and characterization of neuroactive drugs

2017
- 2017-12-21 FI FI20176142A patent/FI128750B/sv not_active IP Right Cessation
2018
- 2018-12-20 WO PCT/FI2018/050954 patent/WO2019122525A1/en not_active Ceased

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12312375B2 (en)	2017-10-09	2025-05-27	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10954259B1 (en)	2017-10-09	2021-03-23	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11149044B2 (en)	2017-10-09	2021-10-19	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11180517B2 (en)	2017-10-09	2021-11-23	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11447510B2 (en)	2017-10-09	2022-09-20	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11505564B2 (en)	2017-10-09	2022-11-22	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12459965B2 (en)	2017-10-09	2025-11-04	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11629159B2 (en)	2017-10-09	2023-04-18	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US10947257B2 (en)	2017-10-09	2021-03-16	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11851451B2 (en)	2017-10-09	2023-12-26	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11939346B2 (en)	2017-10-09	2024-03-26	Compass Pathfinder Limited	Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US11738035B2 (en)	2019-04-17	2023-08-29	Compass Pathfinder Limited	Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US12377112B2 (en)	2019-04-17	2025-08-05	Compass Pathfinder Limited	Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US12433904B2 (en)	2019-04-17	2025-10-07	Compass Pathfinder Limited	Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US12447164B2 (en)	2019-04-17	2025-10-21	Compass Pathfinder Limited	Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
US11564935B2 (en)	2019-04-17	2023-01-31	Compass Pathfinder Limited	Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Also Published As

Publication number	Publication date
WO2019122525A1 (en)	2019-06-27
FI128750B (sv)	2020-11-30

Publication	Publication Date	Title
FI128750B (sv)	2020-11-30	Förfaranden för att fastställa den terapeutiska verkan hos snabbverkande antidepressanter och individualiserad antidepressantterapi i anslutning därtill
Zhou et al.	2020	The effects of repeated transcranial direct current stimulation on sleep quality and depression symptoms in patients with major depression and insomnia
US20240261533A1 (en)	2024-08-08	Systems and methods for driving neural activity to control brain signaling and gene expression
Pavone et al.	2016	Nitrous oxide-induced slow and delta oscillations
Xiao et al.	2008	Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine
Kohtala et al.	2019	Cortical excitability and activation of TrkB signaling during rebound slow oscillations are critical for rapid antidepressant responses
Li et al.	2001	Antidepressant-like actions of an AMPA receptor potentiator (LY392098)
Gener et al.	2019	Serotonin 5-HT1A, 5-HT2A and dopamine D2 receptors strongly influence prefronto-hippocampal neural networks in alert mice: Contribution to the actions of risperidone
Mair et al.	2008	Memory enhancement with event-related stimulation of the rostral intralaminar thalamic nuclei
Ahnaou et al.	2009	Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep–wake architecture
Sood et al.	2006	Inhibition of serotonergic medullary raphe obscurus neurons suppresses genioglossus and diaphragm activities in anesthetized but not conscious rats
Buran et al.	2017	Treatment with TREK1 and TRPC3/6 ion channel inhibitors upregulates microRNA expression in a mouse model of chronic mild stress
Ahnaou et al.	2015	Negative versus positive allosteric modulation of metabotropic glutamate receptors (mGluR5): indices for potential pro-cognitive drug properties based on EEG network oscillations and sleep-wake organization in rats
Matthews et al.	2023	T‐type calcium channels as therapeutic targets in essential tremor and Parkinson's disease
Jonak et al.	2021	The PDE10A inhibitor TAK-063 reverses sound-evoked EEG abnormalities in a mouse model of fragile X syndrome
Raymond et al.	2023	Quiet wakefulness: the influence of intraperitoneal and intranasal oxytocin on sleep–wake behavior and neurophysiology in rats
Griebel et al.	2013	Further evidence for the sleep-promoting effects of 5-HT2A receptor antagonists and demonstration of synergistic effects with the hypnotic, zolpidem in rats
Suzuki et al.	2024	Effects of the orexin receptor 2 agonist danavorexton on emergence from general anaesthesia and opioid-induced sedation, respiratory depression, and analgesia in rats and monkeys
Monti et al.	2013	The effects of systemic and local microinjection into the central nervous system of the selective serotonin 5-HT6 receptor agonist WAY-208466 on sleep and wakefulness in the rat
Kirton et al.	2016	Pediatric brain stimulation: Mapping and modulating the developing brain
Ahnaou et al.	2016	Modulation of mGlu2 receptors, but not PDE10A inhibition normalizes pharmacologically-induced deviance in auditory evoked potentials and oscillations in conscious rats
Philbert et al.	2015	The CRF1 receptor antagonist SSR125543 prevents stress-induced long-lasting sleep disturbances in a mouse model of PTSD: comparison with paroxetine and d-cycloserine
Laitman et al.	2014	The α1 adrenoceptor antagonist prazosin enhances sleep continuity in fear-conditioned Wistar–Kyoto rats
Mota et al.	2023	Acute deep brain stimulation of the paraventricular nucleus of the hypothalamus increases brown adipose tissue thermogenesis in rats
Sanford et al.	2006	Cholinergic regulation of the central nucleus of the amygdala in rats: effects of local microinjections of cholinomimetics and cholinergic antagonists on arousal and sleep

Legal Events

Date	Code	Title	Description
2020-11-30	FG	Patent granted	Ref document number: 128750 Country of ref document: FI Kind code of ref document: B
2022-08-05	MM	Patent lapsed

Date

Code

Title

Description

2020-11-30

Patent granted

Ref document number: 128750

Country of ref document: FI

Kind code of ref document: B

2022-08-05

Patent lapsed